> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Voucher Used on Kisqali sNDA
- URL: https://www.fdaweb.com/priority-voucher-used-on-kisqali-snda/
- Published: 2024-10-14T12:00:00.000Z
- Updated: 2026-09-14T14:43:53.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5157978

*Federal Register* notice: FDA is announcing that it approved on 9/17 a product application that redeemed a priority review voucher —Novartis’ Kisqali (ribociclib) for combination use with an aromatase inhibitor for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative Stage II and III early breast cancer at high risk of recurrence, including those with node-negative disease. Kisqali is described as a selective cyclin-dependent kinase inhibitor that works by slowing cancer progression through its inhibition of proteins cyclin-dependent kinase 4 and 6\. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-10-15/pdf/2024-23651.pdf?ref=fdaweb.com).